The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine.
Czech
J
J
Research Laboratories, Hoechst Marion Roussel Deutschland GmbH, DG Rheumatology, Frankfurt, Germany.
Kurrle
R
R
Schorlemmer
H U
HU
D000178:Acrylamides / Q000494:pharmacology*; D000480:Alkynes; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D002208:Caproates / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D003437:Crotonates; D006885:Hydroxybutyrates / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D009570:Nitriles; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D051381:Rats; D014052:Toluidines; D014529:Uridine / Q000494:pharmacology*
D000178:Acrylamides; D000480:Alkynes; D000814:Aniline Compounds; D002208:Caproates; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D010982:Platelet-Derived Growth Factor; D014052:Toluidines; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; C527525:teriflunomide; C116406:HMR 1279; D014529:Uridine